公开(公告)号：US12070541B2

公开(公告)日：2024-08-27

申请号：US18323077

申请日：2023-05-24

Applicant: Orth Consulting, LLC

Inventor： Donald S. Orth ,  Roger W. Orth

IPC: A61M1/34 ,  A61F2/01 ,  A61F2/95 ,  A61K8/66 ,  A61M1/14 ,  A61M1/16 ,  A61M1/26 ,  A61M1/36 ,  B01D63/02 ,  B01D63/06 ,  B01D69/04 ,  B01D69/08 ,  B01J31/00 ,  C07K16/00 ,  C07K16/38 ,  C07K16/40 ,  C12N9/22 ,  C12N11/00 ,  C12N11/04 ,  C12N11/06 ,  C12N11/14 ,  C12N11/16

CPC classification number: A61M1/3489 ,  A61F2/01 ,  A61F2/95 ,  A61K8/66 ,  A61M1/15632 ,  A61M1/1621 ,  A61M1/1678 ,  A61M1/267 ,  A61M1/36 ,  A61M1/3601 ,  A61M1/3618 ,  A61M1/3621 ,  A61M1/3679 ,  A61M1/3687 ,  A61M1/3689 ,  B01D63/02 ,  B01D63/06 ,  B01D69/04 ,  B01D69/043 ,  B01D69/08 ,  B01J31/00 ,  B01J31/003 ,  C07K16/00 ,  C07K16/38 ,  C07K16/40 ,  C12N9/22 ,  C12N11/00 ,  C12N11/04 ,  C12N11/06 ,  C12N11/14 ,  C12N11/16 ,  A61M2202/0445 ,  A61M2205/3303 ,  A61M2205/3368

Abstract: A blood treatment method includes the steps of inducing flow of a patient's blood through a blood treatment device inlet and outlet in fluid connection to the circulatory system of the patient. Metastatic deoxyribonucleic acid (DNA) contained within patient blood is destroyed by passing a patient's blood over a bioreactor surface having attached or immobilized deoxyribonuclease 1 (DNase 1) enzyme. The blood treatment device which consists of a bioreactor containing immobilized DNase 1, enables continuous treatment of a patient's blood and increases the effective concentration of DNase 1 in a patient's bloodstream to convert metastasizing cancer DNA in blood into non-oncogenic nucleotide fragments in vivo without adding any chemicals to the blood of the patient.

公开(公告)号：US11774447B2

公开(公告)日：2023-10-03

申请号：US16625972

申请日：2018-07-02

Applicant: University of Tsukuba

Inventor： Isao Matsumoto ,  Takayuki Sumida ,  Hoshimi Kawaguchi

IPC: G01N33/564 ,  C07K16/38

CPC classification number: G01N33/564 ,  C07K16/38 ,  G01N2333/811 ,  G01N2440/18

Abstract: This invention provides a method for diagnosis of rheumatoid arthritis of a subject, a method for assisting diagnosis of rheumatoid arthritis, and a method for monitoring disease activity of rheumatoid arthritis and/or therapeutic effects of an agent for rheumatoid arthritis, comprising detecting citrullination of an arginine residue of the inter-α-trypsin inhibitor heavy chain (ITIH) 4 in a biological sample obtained from the subject. This invention also provides a citrullinated protein derived from the protein having the amino acid sequence as shown in SEQ ID NO: 1 or 5 by modification of arginine 438 into citrulline or a fragment thereof, an antibody binding to such citrullinated protein, and an agent for diagnosis of rheumatoid arthritis comprising such antibody.

公开(公告)号：US20190015492A1

公开(公告)日：2019-01-17

申请号：US16116323

申请日：2018-08-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/115 ,  C07K14/72 ,  G01N33/574 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C07K14/71 ,  C12N9/12 ,  C12N9/02 ,  C12N5/0783 ,  G06F19/20 ,  C12Q1/6886 ,  C07K16/40 ,  C07K16/38 ,  C07K16/30 ,  C07K16/28 ,  C07K16/18 ,  C07K14/81 ,  A61K38/00 ,  A61K35/17

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/71 ,  C07K14/721 ,  C07K14/8135 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/0091 ,  C12N9/1264 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Y116/01 ,  C12Y207/07031 ,  G01N33/57484 ,  G01N2333/47 ,  G16B25/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180334509A1

公开(公告)日：2018-11-22

申请号：US15997481

申请日：2018-06-04

Applicant: Bayer HealthCare LLC

Inventor： Zhuozhi WANG ,  John E. MURPHY ,  Junliang PAN ,  Haiyan Jiang ,  Bing LIU

IPC: C07K16/38 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/38 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  A61K2300/00

Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) and the isolated nucleic acid molecules encoding them are provided. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.

公开(公告)号：US20180244759A1

公开(公告)日：2018-08-30

申请号：US15753321

申请日：2016-08-18

Applicant: Rutgers, The State University of New Jersey

Inventor： Stephen Anderson ,  Elliot Campbell

IPC: C07K16/10 ,  C07K16/06 ,  C07K16/20 ,  C07K1/04 ,  A61K9/00

CPC classification number: C07K16/1045 ,  A61K9/0019 ,  C07K1/047 ,  C07K16/00 ,  C07K16/065 ,  C07K16/205 ,  C07K16/38 ,  C07K2317/14 ,  C07K2317/33 ,  C07K2317/92 ,  Y02A50/58

Abstract: The invention describes a method of generating antibodies to a mixture of peptidogenic proteins wherein the peptidogenic protein has altered conformational dynamics as compared to a starting protein and wherein the peptidogenic protein has a similar conformation to the starting protein. The peptidogenic proteins can be used to induce an immune response, which can lead to the generation of antibodies and/or can be used to vaccinate a mammal.

公开(公告)号：US20180162953A1

公开(公告)日：2018-06-14

申请号：US15882936

申请日：2018-01-29

Applicant: ASTUTE MEDICAL, INC.

Inventor： Ravi A. VIJAYENDRAN ,  Srivatsa VENKATASUBBARAO

IPC: C07K16/38 ,  G01N33/577

CPC classification number: C07K16/38 ,  C07K2317/34 ,  G01N33/577 ,  G01N2333/8146

Abstract: The invention provides TIMP2 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.

公开(公告)号：US20170253646A1

公开(公告)日：2017-09-07

申请号：US15477934

申请日：2017-04-03

Applicant: The Penn State Research Foundation

Inventor： Joyce Tombran-Tink ,  Colin J. Barnstable

IPC: C07K14/81 ,  A61K9/00

CPC classification number: C07K14/8121 ,  A61K9/0048 ,  A61K38/00 ,  A61K38/55 ,  C07K7/08 ,  C07K16/38 ,  C07K2317/76 ,  G01N33/5008 ,  G01N33/5023

Abstract: The invention provides compositions and methods relating to bioactive peptide analogs of PEDF.

公开(公告)号：US20170204140A1

公开(公告)日：2017-07-20

申请号：US15328309

申请日：2015-07-23

Applicant: Deakin University

Inventor： Cenk Suphioglu

IPC: C07K7/08 ,  C07K16/38

CPC classification number: C07K7/08 ,  A61K38/00 ,  A61K38/10 ,  A61P25/28 ,  A61P37/08 ,  C07K14/8142 ,  C07K16/38 ,  C07K2317/34

Abstract: The present invention relates to a compositions and methods for treating and/or preventing neurologic disorders such as Alzheimer's disease and disorders associated with an increase of the Th2 immune response such as allergic inflammation.

公开(公告)号：US20170189510A1

公开(公告)日：2017-07-06

申请号：US15375037

申请日：2016-12-09

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/18 ,  C07K14/47 ,  C12N5/0783

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/71 ,  C07K14/721 ,  C07K14/8135 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/0091 ,  C12N9/1264 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Y116/01 ,  C12Y207/07031 ,  G01N33/57484 ,  G01N2333/47 ,  G06F19/20

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20170189508A1

公开(公告)日：2017-07-06

申请号：US15374975

申请日：2016-12-09

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/71 ,  C07K14/721 ,  C07K14/8135 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/2869 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/0091 ,  C12N9/1264 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Y116/01 ,  C12Y207/07031 ,  G01N33/57484 ,  G01N2333/47 ,  G06F19/20

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.